Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) on behalf of Outset stockholders. Our investigation concerns whether Outset has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

Outset provided guidance for the second quarter of 2022 as part of a June 13, 2022 press release. The Company announced that it had “implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the Food and Drug Administration’s (“FDA”) review and clearance of a 510(k) the Company submitted for changes made since the device’s original March 2020 clearance.”

Based on this news, shares of Outset fell by more than 34% on June 14, 2022.

If you purchased or otherwise acquired Outset shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006131/en/